1 company and 6 research reports found for "Cerulean Pharma"
- Cerulean Pharma
Cerulean is a US-based cancer company with a proprietary platform utilizing nanoparticle-drug conjug...
No sector reports have been found.
Cerulean PharmaPharmaceutical & healthcare | 21/09/2016
Edison Investment Research is terminating coverage on Cerulean Pharma (CERU). Please note you should no longer rely on any previous research or estima...
Cerulean PharmaPharmaceutical & healthcare | 24/06/2016
Cerulean recently presented the results on the Phase Ib trial of CRLX101 with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer...
Cerulean PharmaPharmaceutical & healthcare | 17/05/2016
Cerulean reported first quarter results and provided a pipeline update on 2 May, while confirming an expected cash runway for the company into 2017. M...
Cerulean PharmaPharmaceutical & healthcare | 16/03/2016
On 10 March Cerulean reassured the market by reporting in-line full-year 2015 results, reiterating an expected cash runway into 2017 and confirming ti...
Cerulean PharmaPharmaceutical & healthcare | 19/11/2015
Cerulean reported in-line Q3 results on 16 November followed by an investor call highlighting its growing clinical program for treatments using its un...